[17] Soren R Kunzel, Jasjeet S Sekhon, Peter J Bickel, and Bin Yu. Metalearners for estimating heterogeneous treatment effects using machine learning. Proceedings of the national academy of sciences, 116(10):4156-4165, 2019.
[18] John M Lachin. A review of methods for futility stopping based on conditional power. Statistics in Medicine, 24(18):2747-2764, 2005.
[19] Gary Lorden. 2-sprt's and the modified kiefer-weiess problem of minimizing an expected sample size. The Annals of Statistics, pages 281–291, 1976.
[20] Ying Lu and Lu Tian. Statistical considerations for sequential analysis of the restricted mean survival time for randomized clinical trials. Statistics in biopharmaceutical research, 13(2): 210-218, 2021.
[21] Xinkun Nie and Stefan Wager. Quasi-oracle estimation of heterogeneous treatment effects. Biometrika, 108(2):299-319, 2021.
[22] Peter C O'Brien and Thomas R Fleming. A multiple testing procedure for clinical trials. Biometrics, pages 549-556, 1979.
[23] Stuart J Pocock. Group sequential methods in the design and analysis of clinical trials. Biometrika, 64(2):191-199, 1977.
[24] R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2022. URL https://www.R-project.org/.
[25] Aaditya Ramdas, Johannes Ruf, Martin Larsson, and Wouter Koolen. Admissible anytime-valid sequential inference must rely on nonnegative martingales. arXiv preprint arXiv:2009.03167, 2020.
[26] Herbert Robbins. Statistical methods related to the law of the iterated logarithm. The Annals of Mathematical Statistics, 41(5):1397-1409, 1970.
[27] James M Robins, Andrea Rotnitzky, and Lue Ping Zhao. Estimation of regression coefficients when some regressors are not always observed. Journal of the American statistical Association, 89(427):846-866, 1994.
[28] Patrick Royston and Mahesh KB Parmar. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC medical research methodology, 13(1):1-15, 2013.
[29] Benjamin R Saville, Jason T Connor, Gregory D Ayers, and JoAnn Alvarez. The utility of bayesian predictive probabilities for interim monitoring of clinical trials. Clinical Trials, 11(4): 485-493, 2014.
[30] Patrick M Schnell, Qi Tang, Walter W Offen, and Bradley P Carlin. A bayesian credible subgroups approach to identifying patient subgroups with positive treatment effects. Biometrics, 72(4):1026-1036, 2016.
[31] Skipper Seabold and Josef Perktold. statsmodels: Econometric and statistical modeling with python. In 9th Python in Science Conference, 2010.
[32] Aditi Shendre, Gaurav M Parmar, Chrisly Dillon, Timothy Mark Beasley, and Nita A Limdi. Influence of age on warfarin dose, anticoagulation control, and risk of hemorrhage. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 38(6):588-596, 2018.
[33] Chris Stucchio. Bayesian A/B testing at VWO. Whitepaper, Visual Website Optimizer, 2015.
[34] Gail M Sullivan and Richard Feinn. Using effect size—or why the p value is not enough. Journal of graduate medical education, 4(3):279-282, 2012.
[35] Peter F Thall and J Kyle Wathen. Bayesian designs to account for patient heterogeneity in phase ii clinical trials. Current opinion in oncology, 20(4):407, 2008.
[36] Aad W Van der Vaart. Asymptotic statistics, volume 3. Cambridge University Press, 2000.